Three scientists and two teachers were honoured at a black-tie dinner at Parliament House with the Prime Minister's Prizes for Science, Canberra.

Linley Clinic Private Hospital has become the first Melbourne clinic to offer Regeneus's (ASX:RGS) HiQCell, a point-of-care cell therapy for musculoskeletal conditions. [ + ]

Alchemia (ASX:ACL) has received an $8.8m R&D tax incentive windfall, as it benefited from a finding that it can apply for a rebate on some research conducted overseas. [ + ]

Researchers from The University of Western Australia (UWA) have helped develop a nanoparticle light filter system which stimulates the growth of useful microalgal organisms. The resulting microalgal cells, and their light-absorbing photopigments, provide high value-added chemical compounds. [ + ]

Nexvet has closed an oversubscribed capital raising, taking in an extra $7m to support its veterinary biological drug development programs. [ + ]

LabGear Australia has been appointed as a distributor for Grant Instruments and the exclusive distributor in Australia and New Zealand for Planer. Both companies are based in the UK. [ + ]

Rotavirus discoverer honoured with CSL Florey Medal. [ + ]

Medical technology industry body MTAA has announced the appointment of three new board members, and the departure of two more who have served their maximum six-year term. [ + ]

The Victorian Minister for Technology, the Hon Gordon Rich-Phillips, yesterday launched the new 'Guide for Life Science Company Directors' at the opening of Australia’s biggest biotech investment event in this part of the world to date - Australia Biotech Invest 2013. [ + ]

A Japanese licensee to Mesoblast's MSC technology will soon file for regulatory approval in the market for a treatment for steroid-refractory GvHD. [ + ]

ResMed (ASX:RMD) said its revenue for the September quarter increased 5%, despite what CEO Mick Farrell called a "tough competitive product cycle". [ + ]

The Association of Australian Medical Research Institutes celebrates its 20th birthday this week. [ + ]

During a phase II trial, Biotron's (ASX:BIT) BIT225 has shown promise at enhancing antiviral activity in hard-to-treat HCV Genotype 3 patients undergoing the IFN/RVB treatment regimen. [ + ]

Annual survey shows rates of chlamydia, gonorrhoea and syphilis infection are on the increase. [ + ]

iCeutica has won FDA approval for Zorvolex, the first drug developed using a technology platform conceived at the University of Western Australia. [ + ]